1. Advances in targeted therapies for metastatic colorectal cancer. Issue 3 (May 2009) Authors: Perez-Garcia, Jose; Capdevila, Jaume; Macarulla, Teresa; Ramos, Francisco Javier; Elez, Elena; Ruiz-Echarri, Manuel; Tabernero, Josep Journal: Therapy Issue: Volume 6:Issue 3(2008) Page Start: 321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. Issue 1 (5th July 2019) Authors: Sclafani, Francesco; Wilson, Sanna Hulkki; Cunningham, David; Gonzalez De Castro, David; Kalaitzaki, Eleftheria; Begum, Ruwaida; Wotherspoon, Andrew; Capdevila, Jaume; Glimelius, Bengt; Roselló, Susana; Thomas, Janet; Tait, Daina; Brown, Gina; Oates, Jacqui; Chau, Ian Journal: International journal of cancer Issue: Volume 146:Issue 1(2020) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Issue 9 (20th July 2017) Authors: Dienstmann, Rodrigo; Elez, Elena; Argiles, Guillem; Matos, Ignacio; Sanz‐Garcia, Enrique; Ortiz, Carolina; Macarulla, Teresa; Capdevila, Jaume; Alsina, Maria; Sauri, Tamara; Verdaguer, Helena; Vilaro, Marta; Ruiz‐Pace, Fiorella; Viaplana, Cristina; Garcia, Ariadna; Landolfi, Stefania; Palmer, Hec... Journal: Molecular oncology Issue: Volume 11:Issue 9(2017) Page Start: 1263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Issue 3 (7th January 2016) Authors: Caplin, Martyn E; Pavel, Marianne; Ćwikła, Jarosław B; Phan, Alexandria T; Raderer, Markus; Sedláčková, Eva; Cadiot, Guillaume; Wolin, Edward M; Capdevila, Jaume; Wall, Lucy; Rindi, Guido; Langley, Alison; Martinez, Séverine; Gomez-Panzani, Edda; Ruszniewski, Philippe Journal: Endocrine-related cancer Issue: Volume 23:Issue 3(2016) Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Issue 4 (October 2017) Authors: Capdevila, Jaume; Trigo, José Manuel; Aller, Javier; Manzano, José Luís; Adrián, Silvia García; Llopis, Carles Zafón; Reig, Òscar; Bohn, Uriel; Cajal, Teresa Ramón y; Duran-Poveda, Manuel; Astorga, Beatriz González; López-Alfonso, Ana; Martínez, Javier Medina; Porras, Ignacio; Reina, Juan Jose; P... Journal: European journal of endocrinology Issue: Volume 177:Issue 4(2017) Page Start: 309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. (July 2022) Authors: Castellano, Daniel; Apolo, Andrea B.; Porta, Camillo; Capdevila, Jaume; Viteri, Santiago; Rodriguez-Antona, Cristina; Martin, Lidia; Maroto, Pablo Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial. Issue 24 (19th October 2022) Authors: Brose, Marcia S.; Robinson, Bruce G.; Sherman, Steven I.; Jarzab, Barbara; Lin, Chia‐Chi; Vaisman, Fernanda; Hoff, Ana O.; Hitre, Erika; Bowles, Daniel W.; Sen, Suvajit; Oliver, Jennifer W.; Banerjee, Kamalika; Keam, Bhumsuk; Capdevila, Jaume Journal: Cancer Issue: Volume 128:Issue 24(2022) Page Start: 4203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 8 (August 2021) Authors: Brose, Marcia S; Robinson, Bruce; Sherman, Steven I; Krajewska, Jolanta; Lin, Chia-Chi; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Hernando, Jorge; Faoro, Leonardo; Banerjee, Kamalika; Oliver, Jennifer W; Keam, Bhumsuk; Capdevila, Jaume Journal: Lancet oncology Issue: Volume 22:Issue 8(2021) Page Start: 1126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Cabozantinib for the treatment of solid tumors: a systematic review. (June 2022) Authors: Maroto, Pablo; Porta, Camillo; Capdevila, Jaume; Apolo, Andrea B.; Viteri, Santiago; Rodriguez-Antona, Cristina; Martin, Lidia; Castellano, Daniel Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. (March 2017) Authors: Crespo, Guillermo; Jiménez-Fonseca, Paula; Custodio, Ana; López, Carlos; Carmona-Bayonas, Alberto; Alonso, Vicente; Navarro, Miguel; Aller, Javier; Sevilla, Isabel; Grande, Enrique; Gajate, Pablo; Alonso-Gordoa, Teresa; Matos, Ignacio; Capdevila, Jaume; Nieto, Beatriz; Barriuso, Jorge Journal: Future oncology Issue: Volume 13:Number 7(2017) Page Start: 615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗